Maria is responsible for the innovative Cancer Research UK (CRUK) MedImmune Alliance Laboratory. She heads up and will lead a multi-disciplinary team of 14 scientists from both CRUK and MedImmune at this CRUK-funded facility.
The laboratory utilizes MedImmune's and AstraZeneca’s core Antibody Discovery and Protein Engineering technologies and capabilities to discover new medicines for the potential treatment of cancer. This innovative Alliance has access to the CRUK oncology Principal Investigator (PI) network, which represents over 4000 laboratories throughout the UK. Maria leads the Alliance team to work with selected PIs on five new projects each year for the five-year term of the Alliance.
Maria is also an industry recognized expert and leader in the field of ribosome display and protein engineering. She joined the company (Cambridge Antibody Technology/MedImmune Ltd.) in 2000 and established herself as an externally recognised scientific expert in ribosome display.
As a project leader, her biggest success to date has been leading the R&D phase of MEDI1814 - an antibody therapeutic for the treatment of Alzheimer’s Disease which is now in phase 1 clinical trials.
Leading a new venture for AstraZeneca.
Head of the Cancer Research UK MedImmune Alliance Laboratory
IBC Antibody Engineering Conference Presenter 2014
MEDI1814 for Alzheimer’s Disease
Candidate Drug nomination in 2012
Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope “tags”
Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope “tags”. Percival-Alwyn, J.L., England, E., Kemp, B., Rapley, L., Davis, H.E., Davis, N. H. E., McCarthy, G. R., Majithiya, J. B., Corkhill, D., Welsted, S., Minton, K., Cohen, E. S., Robinson, M. J., Dobson, C., Wilkinson, T. C. I., Groves, M. A. T and Tigue, N. J. mAbs, 2015. 7(1): p. 129-137.
Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity
Antibody VH and VL Recombination using Phage and Ribosome Display Technologies Reveals Distinct Structural Routes to Affinity Improvements with VH-VL Interface Residues providing Important Structural Diversity. Groves, M.A., Amanuel, L., Campbell, J. I., Rees, G.D., Sridharan, S., Finch, D.K., Lowe, D.C and Vaughan, T. J, mAbs, 2013. vol 6 (1): p. 61-68.
An efficient and easily accessible eukaryotic ribosome display technology
Douthwaite, J.A., Groves, M.A and Dufner, P. Protein Eng. Des Sel, 2006. 19(2): p. 85-90.
Affinity Maturation of Phage Display Antibody Populations Using Ribosome Display
Groves, M., Lane, S., Douthwaite, J., Lowne, D., Rees, G. D., Edwards B, and Jackson, R. H. J Immunol. Methods, 2006. 313(1-2): p. 129-39.
Awards and honours
Significant contributions to CMAL Alliance
Successful Candidate Drug nomination for MEDI1814
I am really excited to be able to play a significant role in the new Alliance Laboratory with Cancer Research UK. Collaborating with CRUK and accessing oncology knowledge from the scientists within those thousands of groups is going to help us to find some really novel targets so we can generate innovative therapeutics to help cancer patients.
Join us at MedImmune
Our Great Place to Work strategic initiative offers a dynamic environment that fosters collaboration and innovation. We attract top minds, and we do what it takes to nurture and build talent.